65,437 trials
Midface Volume Deficit
Primary: Percent Responders With 1 Point Improvement on the Medicis Midface Volume Scale — 67; 8 Participants
Rheumatoid Arthritis
Primary: Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response — 96; 84; 28 Participants — p=0.004
Diaphragm Pacing
Primary: Number of Participant That Experience Adverse Procedure and/or Device Effects — 0 Events
Pain Control After Functional Endoscopic Sinus Surgery and Septoplasty
Primary: Pain Score as Assessed by a 100mm Visual Analogue Scale (VAS) — 30.2; 40.7 units on a scale
Opioid-use Disorder
Primary: Intervention Feasibility — 7; 8 Participants
Healthy Adult Male
Primary: Maximum (Peak) Plasma Concentration (Cmax) of Brexpiprazole — 23.31; 24.24; 23.75 ng/mL
Colitis, Ulcerative
Primary: Clinical Improvement Rate (Number of Subjects Showing Clinical Improvement/Number of Subjects Evaluated x 100) — 31.4; 24.1; 44.4; 30.0 percentage of participants
Heart Failure
Primary: Time to Cardiovascular Death or First Heart Failure Event — 39.1; 37.0 percentage of participants — p=0.0252
Breastfeeding
Primary: Number of Participants Breastfeeding Without Formula Supplementation — 30; 30 Participants
Polycythemia Vera
Primary: Number of Participants Achieving Hematocrit (Hct) Control at Week 28 — 46; 14 Participants
Neoplasms
Primary: Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs (STEAEs) — 9; 6; 9; 4 Participants
Myelodysplastic Syndrome
Primary: Response Signature in Transfusion Dependent MDS Patients — 24; 1; 17; 6 Participants
Malignant Pleural Mesothelioma · Solid Tumors
Primary: 4M PFS Rate of Patients With Previously Untreated, Unresectable Malignant Pleural Mesothelioma (MPM) Treated With CBP501, Pemetrexed and Cisplatin — 25; 9; 27; 13…
Lower Extremity Lymphoedema · Leg Lymphoedema
Primary: Limb Volume (ml) — -197; -60; 45 ml
Colorectal Neoplasms
Primary: Overall Response Rate — 2.4 months